stars 1 stars 2 stars 3

Meditech is an Australian biotechnology company focused on developing and commercialising drugs that improve the health and quality of life of patients with cancer and other chronic diseases. The company has internationally recognised expertise in carbohydrate-based therapies, particularly products based upon the glycosaminoglycan, hyaluronic acid. Building on this expertise, Meditech has created its patented HyACTTM (Hyaluronic Acid Chemotransport Technology) platform which it is applying to the development of improved formulations of cancer drugs. The lead product from the HyACTĂ” platform is HyCAMPĂ”. In addition to HyCAMPTM, Meditech has taken the anti-cancer products HyDOXTM (doxorubicin and hyaluronic acid) and HyFIVETM (5-fluorouracil and hyaluronic acid) into clinical testing.

MIS.CARBONART Questions

The MIS.CARBONART annual revenue was $14 million in 2026.

2 people are employed at MIS.CARBONART.

MIS.CARBONART is based in Perth, Western Australia.

The NAICS codes for MIS.CARBONART are [54, 541, 5417].

The SIC codes for MIS.CARBONART are [87, 873].

Top MIS.CARBONART Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users